CACNA1C mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma.

Aims: There is an urgent need for appropriate biomarkers that can precisely and reliably predict immunotherapy efficacy, as immunotherapy responses can differ in skin cutaneous melanoma (SKCM) patients. Methods: In this study, univariate regression models and survival analysis were used to examine the link between calcium voltage-gated channel subunit alpha 1C (CACNA1C) mutation status and immunotherapy outcome in SKCM patients receiving immunotherapy. Mutational landscape, immunogenicity, tumor microenvironment and pathway-enrichment analyses were also performed. Results: The CACNA1C mutation group had a better prognosis, higher immunogenicity, lower endothelial cell infiltration, significant enrichment of antitumor immune response pathways and significant downregulation of protumor pathways. Conclusion: CACNA1C mutation status is anticipated to be a biomarker for predicting melanoma immunotherapy effectiveness.

[1]  Zi-Ming Wang,et al.  Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma , 2023, Journal of thoracic disease.

[2]  H. Körner,et al.  Tumor Necrosis Factor: What Is in a Name? , 2022, Cancers.

[3]  B. Zeng,et al.  Human cancer cells generate spontaneous calcium transients and intercellular waves that modulate tumor growth. , 2022, Biomaterials.

[4]  Yongting Luo,et al.  The Regulatory Roles of Mitochondrial Calcium and the Mitochondrial Calcium Uniporter in Tumor Cells , 2022, International journal of molecular sciences.

[5]  Alexander M. Wathen,et al.  BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. , 2022, Cellular signalling.

[6]  J. Marsh,et al.  Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations: Beyond the Loss-of-Function Paradigm. , 2022, Annual review of genomics and human genetics.

[7]  P. Murray,et al.  Calcium-dependent signalling in B-cell lymphomas , 2021, Oncogene.

[8]  R. Houlgatte,et al.  Integrative genomics analysis of nasal intestinal-type adenocarcinomas demonstrates the major role of CACNA1C and paves the way for a simple diagnostic tool in male woodworkers , 2021, Clinical epigenetics.

[9]  Xiaohan Chang,et al.  CACNA1C is a prognostic predictor for patients with ovarian cancer , 2021, Journal of Ovarian Research.

[10]  Jian Zhang,et al.  Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma , 2021, Frontiers in Molecular Biosciences.

[11]  D. Bello,et al.  Adjuvant immunotherapy for melanoma , 2021, Journal of surgical oncology.

[12]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[13]  M. Mercogliano,et al.  Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy , 2021, Cancers.

[14]  Qiong Zhang,et al.  Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response , 2020, Briefings Bioinform..

[15]  Aleksandra A. Kolodziejczyk,et al.  Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy , 2020, Nature Cell Biology.

[16]  Shijun Kang,et al.  ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer , 2020, Cancer Immunology, Immunotherapy.

[17]  Takashi Ando,et al.  Aspirin Induces Mitochondrial Ca2+ Remodeling in Tumor Cells via ROS‒Depolarization‒Voltage-Gated Ca2+ Entry , 2020, International journal of molecular sciences.

[18]  Jin-liang Wang,et al.  Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer , 2020, Targeted Oncology.

[19]  L. Fu,et al.  The immune landscape of esophageal cancer , 2019, Cancer communications.

[20]  A. Scarpa,et al.  ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Xu,et al.  Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? , 2019, Cancer communications.

[22]  E. V. Van Allen,et al.  Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.

[23]  A. Richmond,et al.  Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy , 2019, Front. Immunol..

[24]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[25]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[26]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[28]  G. Getz,et al.  Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors , 2018, Nature Genetics.

[29]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[30]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[31]  Betty Y. S. Kim,et al.  Improving immune–vascular crosstalk for cancer immunotherapy , 2018, Nature Reviews Immunology.

[32]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[33]  Y. Kienast,et al.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.

[34]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[35]  K. Martin,et al.  Altering calcium influx for selective destruction of breast tumor , 2017, BMC Cancer.

[36]  P. A. Futreal,et al.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.

[37]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[38]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[39]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[40]  S. Turley,et al.  Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.

[41]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[43]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[44]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[45]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[46]  Eli Gilboa,et al.  The determinants of tumour immunogenicity , 2012, Nature Reviews Cancer.

[47]  S. Quezada,et al.  Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma , 2008, The Journal of experimental medicine.

[48]  A. Scharenberg,et al.  Calcium signalling and cell-fate choice in B cells , 2007, Nature Reviews Immunology.

[49]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. D. de Gruijl,et al.  Predictions of skin cancer incidence in the Netherlands up to 2015 , 2005, The British journal of dermatology.

[51]  J. Wilde,et al.  Rituxan (anti‐CD20 antibody)‐induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis , 2005, Clinical and experimental immunology.

[52]  OUP accepted manuscript , 2022, Briefings In Bioinformatics.

[53]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[54]  Bruce K Armstrong,et al.  Clinical Features Associated With Individuals at Higher Risk of Melanoma: A Population-Based Study , 2017, JAMA dermatology.

[55]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.